Using multi-omics technology & big data analysis, we identified novel biomarkers & integrated into one-stop diagnostic platform (ELISA & multiplex PCR), which can obtain results within 4 hours. "Smart Anti-Inflammation" testing enables precision treatment with JAKi and maximizing clinical benefits. The product has been granted two domestic patents, won the 2024/2025 National Innovation Award and 2025 Taipei Biotech Awards completed a global patent layout, showing strong market competitiveness.

"Smart Anti-Inflammation” is the world’s first product to predict JAKi efficacy by using multi-omics technology & big data analysis, 
  
  1. Peptidomics: Identify novel peptides by PhIP-Seq & validate biomarkers (SNRK & HUWE1 AutoAbs) by ELISA.
  
  2. Genomics (WES): Identify RIN3, NLRC3, SLX4 genes & multiplex-PCR assay predict remission (high specificity 97% & accuracy 88%)
  
Compared to main competitor, the advantages of our product: comprehensively predict JAKi efficacy with fast results & low price.

Smart Anti-Inflammation is the world＇s first platform predicting JAK inhibitor response in RA patients, targeting a $2.6B global market. Entering via LDTs to bridge diagnostics and clinical use, it delivers high pharmacoeconomic value to health insurance systems, medical centers, and patients by maximizing efficacy and reducing waste. Our core technology is protected by a Taiwanese patent and a comprehensive PCT international patent portfolio, ensuring a solid foundation for global expansion.